Technical Resilience: Market observers noted Abbott Laboratories shares holding firm near key levels amid broader healthcare sector movements. Discussions highlighted potential for continued upward momentum based on recent structural patterns. Analysts on social media pointed to sustained interest in the stock's positioning for possible gains.
Diagnostic Developments: Conversations centered on the company's advancements in blood-based testing for conditions like Alzheimer's, with partnerships drawing attention as a growth driver. Participants emphasized how these innovations could support long-term fundamentals despite fluctuating quarterly results. The dialogue reflected ongoing scrutiny of how such initiatives might influence overall performance.
Earnings Scrutiny: Some commentary addressed recent profit margins and income trends, questioning whether revenue increases sufficiently offset declines in operating metrics. Views ranged from optimism over defensive qualities to caution about potential challenges in sustaining growth. Overall, the tone suggested balanced consideration of both opportunities and risks.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 12 times in the past 6 months. Of those trades, 6 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) purchased 18,800 shares for an estimated $2,013,966
- DANIEL J STARKS has made 3 purchases buying 20,000 shares for an estimated $2,013,868 and 0 sales.
- PHILIP P BOUDREAU (EVP AND CFO) purchased 2,200 shares for an estimated $201,300
- JOHN G STRATTON purchased 2,000 shares for an estimated $173,640
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 1,144 shares for an estimated $132,223
- DANIEL GESUA SIVE SALVADORI (EVP AND GROUP PRESIDENT) sold 885 shares for an estimated $102,288
- ERIC SHROFF (Senior Vice President) sold 709 shares for an estimated $81,946
- MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 613 shares for an estimated $70,850
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 585 shares for an estimated $67,614
- ELIZABETH C. CUSHMAN (EVP, GC AND SECRETARY) sold 263 shares for an estimated $30,397
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Abbott Laboratories Revenue
Abbott Laboratories had revenues of $11.2B in Q1 2026. This is an increase of 7.78% from the same period in the prior year.
You can track ABT financials on Quiver Quantitative's ABT stock page.
You can access data on ABT stock through the Quiver Quantitative API.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICK LARSEN sold up to $15,000 on 07/08.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 06/16 and 2 sales worth up to $30,000 on 05/15, 02/10.
- REPRESENTATIVE RICHARD MCCORMICK has traded it 3 times. They made 3 purchases worth up to $45,000 on 06/12, 03/19 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/27.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 05/12.
- REPRESENTATIVE RICK W. ALLEN sold up to $50,000 on 04/16.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 01/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Abbott Laboratories Hedge Fund Activity
We have seen 1,140 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,603 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP removed 39,003,051 shares (-99.2%) from their portfolio in Q1 2026, for an estimated $3,959,199,707
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 32,310,527 shares (+245.0%) to their portfolio in Q1 2026, for an estimated $3,279,841,595
- CAPITAL INTERNATIONAL INVESTORS removed 25,731,218 shares (-40.7%) from their portfolio in Q1 2026, for an estimated $2,611,975,939
- FISHER ASSET MANAGEMENT, LLC removed 10,688,150 shares (-93.4%) from their portfolio in Q1 2026, for an estimated $1,084,954,106
- CAPITAL RESEARCH GLOBAL INVESTORS added 10,606,123 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $1,076,627,545
- FRANKLIN RESOURCES INC added 8,867,817 shares (+79.5%) to their portfolio in Q1 2026, for an estimated $900,172,103
- CAPITAL WORLD INVESTORS removed 8,466,861 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $859,471,060
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Abbott Laboratories Government Contracts
We have seen $123,852,028 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING ADDING EQUIPMENT FOR MANCHESTER NH VAMC - WITHIN ORIGINAL SCOPE: $4,335,000
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR) PRICE SCHEDULE UPDATE: $4,000,483
- LAB CHEMISTRY SERVICES: $3,620,964
- CIVILIAN DRUG FREE WORKPLACE COLLECTIONS AND MEDICAL REVIEW SUPPORT SERVICES.: $3,510,144
- EXERCISING OPTION YEAR 2: $2,600,297
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Abbott Laboratories Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 02/02/2026
- BTIG issued a "Buy" rating on 01/23/2026
To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 13 analysts offer price targets for $ABT in the last 6 months, with a median target of $121.0.
Here are some recent targets:
- Vijay Kumar from Evercore ISI Group set a target price of $112.0 on 07/06/2026
- David Rescott from Baird set a target price of $121.0 on 07/01/2026
- Adam Maeder from Piper Sandler set a target price of $115.0 on 06/22/2026
- Marie Thibault from BTIG set a target price of $131.0 on 04/27/2026
- Matt Miksic from Barclays set a target price of $143.0 on 04/20/2026
- Travis Steed from B of A Securities set a target price of $120.0 on 04/17/2026
- Suraj Kalia from Oppenheimer set a target price of $115.0 on 04/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
